FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Study: Pathology of multiple sclerosis

 

A casual conversation in a hockey locker room prompted a business partnership & research that may lead to new drug that may help MSers

 

MS LOL OF THE MONTH: Apitherapy -- could therapy based on bee venom sting conventional medicine?

 

Moody's upgrades Biogen's credit on strong MS drug sales

 

Video: New MS Treatment now available in Canada but not the US: more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years. !

Watch this video to see how during an extensive, ongoing clinical development program, 80 per cent of RRMS patients who received two treatment courses of LEMTRADA required no further therapy and 55 per cent remained relapse-free through the first year of the extension study. Unlike other current disease modifying therapies in which stopping treatment usually results in resumed disease activity, LEMTRADA continues to have a durable effect far beyond the two annual treatment courses. In fact, in more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years.
Read more

Labels: ,


 

Researchers comparing the blood of 16 healthy people who later developed multiple sclerosis (MS), with the blood of 16 healthy people of the same age and sex who did not develop MS, believe they have found an antibody that could predict the disease before

 

5 Tips for Managing Stress With MS - CNN

 

Hippotherapy For Multiple Sclerosis Makes Horse Sense

 

Gentle yoga an alternative for MSers

Thursday

 

Study: Tobacco smoking and excess mortality in multiple sclerosis: Journal of Neurology, Neurosurgery & Psychiatry

 

Dang! Richard Pryor Was An Incredible Singer Too? (Take A Look!)

 

New Patent: Pregnancy hormone combination for treatment of MS: US Patent 8658627 Abstract

 

A personal story about dealing with family emergencies while having multiple sclerosis

 

Vitamin D Levels Appear to Be Robust Predictor of MS Progression

 

30 year old teacher with MS inspires students, wins dream vacation

 

The Most Radical Innovation to Zippers in Over a Century helps MSers

 

MSer Fights More than Fires

Most people don't fight multiple sclerosis while running a full-time business and being a volunteer firefighter on the side. But Aimee Lambert, 30 isn't most people.
"I don't like to let things stop me," explains Aimee, who took a break on a recent day, to talk about her life, her disease, her work, and her volunteering. "I can only talk a few minutes," says Aimee, "I've got to get back to work."
Aimee's "work" is running Wags & Whiskers, a pet-grooming business. But, typically, Aimee does her business a bit different than most-she drives a mobile van and comes to the client's house, doing the grooming there. When not grooming animals, Aimee is volunteer firefighter.
read more

 

Study: Factors associated with accidental falls in MSers

 

Study: The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis

 

Receptos released positive results in a mid-stage trial of its Multiple Sclerosis drug — RPC1063

Wednesday

 

"Yes, I have MS -- my life with multiple sclerosis" by Janice Dean, senior meteorologist for Fox News Channel

I had my first Multiple Sclerosis (MS) episode in 2005 (the formal diagnosis would come later). Naturally, I remember it well: we had just come off the most active hurricane season in history.   It was the year of Hurricanes Dennis, Emily, Katrina, Rita and Wilma. We had so many storms, the National Hurricane Center went to the Greek alphabet because we had run out of names.
I was working long hours that fall and was feeling overwhelmingly tired, stressed and depressed from all the devastation we were seeing on television.  Little did I know that as I was warning people of the next hurricane, my body was dealing with its own neurological storm, one that had been forming for years. read more

 

Obesity at age 20 may be associated with increased risk of MS

Multiple sclerosis shows a "striking" association with obesity at age 20 years that strongly interacts with genetic susceptibility, according to an analysis of data from two case-control studies that examined environmental and genetic risk factors for MS.
Read more »

 

Pregnancy outcomes in the clinical development program of Gilenyq (fingolimod) in multiple sclerosis

Read how this study Concludes: Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation.
read more

 

Study: Multiple sclerosis progression linked to whole brain atrophy


The progression of disability in patients with multiple sclerosis was associated with whole brain, cortical, and putamen atrophy during the first 5 years after diagnosis, driven chiefly by a greater decline in gray matter than in white matter volume, according to a report published online in Journal of Neurology, Neurosurgery & Psychiatry.
To identify markers of disability progression in MS, researchers assessed 81 patients residing in Southwestern Norway who were diagnosed in 1998 or 2000 and underwent full neurologic assessments and brain MRI at that time, as well as 5 and 10 years later. Patients whose disability progressed, based on the Expanded Disability Status Scale, during follow-up were no different from those whose disability remained stable in demographic factors, MS subtype, or the use or duration of disease-modifying treatment, said Dr. Cecilie Jacobsen of the department of neurology at Stavanger (Norway) University Hospital and the Neuroimaging Analysis Center at the State University of New York at Buffalo, and her associates.
At 5 years, disease progression was associated with significantly greater volume declines in patients with disease than in those without in measurements of the whole brain (–3.8% vs. –2.0%), cortex (–3.4% vs. –1.8%), and putamen (–10.6% vs. –3.8%). However, at 10 years, there was only a nonsignificant trend toward decreased whole brain volume among patients with disease progression. The correlation was much stronger between disability progression and the decline in gray matter volume than it was between disability progression and the decline in white matter volume. "These findings strengthen the increasing evidence that [gray matter] pathology may be playing a crucial role in MS-related disability progression," the investigators wrote (J. Neurol. Neurosurg. Psychiatry 2014 Feb. 19 [doi:10.1136/jnnp-2013-306906]).
read more

 

Playing Video Games Could Help MSers Restore Balance

 

Study: Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS

 

MS researchers win Thermo Scientific Cellome Award for this Study: A regenerative approach to the treatment of multiple sclerosis

 

The CCSVI theory that constricted neck veins are to blame for MS has been dealt a fatal blow by a University of B.C.-led study published in the Lancet Tuesday.

 

Discriminatory Disease Exploring the gender gap in multiple sclerosis

 

10 year old MSer Lucy Wood had her hair cut off to help raise funds for 2 year old cancer victim, Bradley Lowery

BRAVE 10 year old Lucy Wood may suffer from multiple sclerosis but she never stops thinking of others.
The ten-year-old has needed hospital treatment for the debilitating illness ever since she was five.
But she has still made time to raise money for charity by having her hair chopped off to support poorly youngster Bradley Lowery.
Now, the two of them are best of friends and, like Bradley, Lucy has now been nominated for a Pride of Hartlepool award.

 

?!?!?! "Potential cure for multiple sclerosis to be tested" from the The Japan Times

Tuesday

 

FREE DOWNLOAD: "Multiple Sclerosis...Sex, intimacy and relationships"

 
Although sexual difficulties are common among the population as a whole, MS can bring about particular problems for both men and women

Not everyone with MS will experience sexual problems and, as with other MS symptoms, it is impossible to predict who will be affected and how long symptoms may last. There are techniques that can improve communication and understanding, and help you to adapt to new dynamics within your relationships. Many people, both with and without MS, have successful and satisfying relationships despite experiencing sexual difficulties. This booklet covers:
Read more »

 

Proof that dogs really are MSers' best friends: Meet Amber, the 'wonder-dog' who answers the phone, takes out the laundry and makes the bed

Amber
Just two years ago, Helen Bree was at her lowest point and facing a bleak future.  MS finally forced her to retire from the job she loved after almost 30 years. The independence she had relished – her own house and worldwide travel – suddenly seemed about to come to an abrupt end. But then she met Amber, the ginger-haired Labrador/golden retriever who turned the 57-year-old’s life around. ‘She’s been the best thing to happen to me in years what I’d do without her, I really don’t know,’ Read more








 

STUDY: Neurofilament light antibodies in serum reflect response to Tysabri(natalizumab) treatment in multiple sclerosis

 

Study: Home-based system for physical activity monitoring in patients with multiple sclerosis (Pilot study)

 

Study: When patient opinion and clinical science are implacably opposed: the view from an MS specialist

 

Study: Gender and autoimmune comorbidity in multiple sclerosis

 

HERE'S ANOTHER OF THE MANY ARTICLES THAT SAYS TECFIDERA IS WONDERFUL BUT: NO ONE KNOWS HOW IT WORKS?!?!

Tecfidera is a modified version of a treatment that was originally used to treat the skin disease psoriasis. ‘Nobody is sure exactly how it works,’ explains Belinda Weller, consultant neurologist at the Anne Rowling Regenerative Neurological Clinic in Edinburgh.‘It’s a new approach to treating MS which is believed to help  cells in the body defend themselves against the damage caused by MS.’ Read more

Labels:


 

Could Sleep Problems Make MSers Fatigue Worse?

 

Study: Modafinil combined with cognitive training is associated with improved learning in healthy volunteers - A randomised controlled trial

Abstract
Read more »

 

Study: Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions

 

Physician Entrepreneurs Are Reinventing Themselves because they believe they may have the next great idea for healthcare

 

Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis

 

Is Normal Pressure Hydrocephalus A Component of Multiple Sclerosis Pathology?

 

Britain's regulatory agency turns down Biogen Idec’s oral MS drug Tecfidera

Monday

 

New book by MSer Yvonne Decelis: It's Not as Bad as it Sounds (my life with MS & Fibro)

 
CLICK TO ORDER ON AMAZON
Yvonne Decelis was diagnosed with relapsing-remitting Multiple Sclerosis (MS) in 1994. She later found out (in 2010) that she had Fibromyalgia. From  the time she found out about the MS she joined a support group that helped inspire her to do work to advocate for others in similar situations.

Her goal as an author is to educate people on possible ways to improve their quality of life and to let them know they are not alone. She also hopes to help loved ones, friends and colleagues understand things that patients go through day-to-day.
Read more »

 

Yvonne Decelis-Nicholls, Columnist & News Editor, MSnewsChannel.com

Yvonne Decelis-Nicholls
MY MS DIAGNOSIS
I have relapsing remitting Multiple Sclerosis (and Fibromyalgia as well). I was diagnosed with MS in December of 1994 but I am fairly certain I have had it all my life. I was born with a tremor, was sick as a child (constantly) and had a host of problems that MS would explain. I don't think that the kids who bullied me in school would have been kinder to me had they been aware I had a disease but that is something I will never know. I was terrible at all things  gym related and I had issues with my shake and my balance that I got made fun of over on a constant basis.

Read more »

 

THE AMAZING DOCTOR WHO WAS PART OF A TEAM WHO HELPED INVENT COPAXONE & REBIF & IS NOW FOCUSING ON STEM CELLS AT 75


Six months after his 75th birthday, after teaching generations of young graduate and post-doctoral students at the Weizmann Institute of Science and with a wife, four children and 12 grandchildren, one could expect Prof. Michel Revel to sit back and enjoy life. Yet, the Frenchborn, internationally acclaimed molecular geneticist, who invented a major drug to treat multiple sclerosis used around the world and received the Israel Prize, EMET Prize and other major awards, has his eyes fixed on the future.
Read more »

Labels: ,


 

1,500 Participants to Climb 66 Floors at Rock Center Raising Funds for Multiple Sclerosis

The New York City - Southern New York Chapter of the National Multiple Sclerosis Society will host Climb to the Top on Sunday, March 2, 2014, at 6:30 a.m. at 30 Rockefeller Plaza. 
Read more »

 

Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial

 

MSer Becomes First Disabled Man to Skydive Over Mount Everest

 

Multiple sclerosis genetics: leaving no stone unturned

 

First map of core white matter connections reveals that not all brain connections are equally important

 

Study: Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis

 

Stem Cells Stop the Train of MS Damage in Mice: Neural precursors derived from mature tissues rebuild myelin in mice with EAE

 

A new guideline on “Assessment and Management of Psychiatric Disorders in Individuals with Multiple Sclerosis” from the American Academy of Neurology was recently published

 

Study: What are exosomes and how can they be used in multiple sclerosis therapy?

 

The Consortium of Multiple Sclerosis Centers (CMSC) recently announced that this year’s 28th AnnualMultiple Sclerosis meeting will take place in Dallas, Texas on May 28-31

Sunday

 

22 Photo Slideshow: The Medscape Physician Lifestyle Report 2014 reveals both good and bad eating habits among physicians including their favorite diets

 

Autologous haematopoietic stem cell transplantation is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centers

STUDY: Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. RESULTS: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status
Read more »

 

A wheelchair-bound MSer performer has staged a play to highlight her condition at one of London's most well-known venues.

 

Study: People suffering from schizophrenia face a greater risk of developing autoimmune diseases, such as psoriasis and multiple sclerosis

 

Plea not to cut beds for MS & Parkinson’s Patients

 

Green Tea, Blueberry Supplement May Improve Cognition

 

Dr. Sanjay Gupta: "Keeping track of thinning retinas can help predict multiple sclerosis relapses, in which symptoms recur as isolated flare-ups"

Study found that patients with MS relapses had 42 percent faster retinal thinning than those without relapses. The study’s authors noted that the findings may suggest that retinal thinning occurs faster in patients with more active MS.
read more

 

Biogen Idec hits its first price hurdle for Tecfidera in the EU: Is told that the drug's cost is not justified by its benefits

 

Thugs Controlled Pill Mill Doctors at Gunpoint, Feds Say

 

Study: Brief cognitive-behavioral therapy for insomnia (CBTi) can reduce healthcare utilization and costs

 

Exercise & A New Particle to Fight Multiple Sclerosis and Brain Aging

 

Eight reasons why Pilates is great exercise for someone with Multiple Sclerosis

read more

Labels:


Saturday

 

UPDATE: Jody Corey-Bloom, M.D., PH.D Professor of Neurosciences Director of the UC San Diego MS Center University of California, San Diego


"SMOKING MARIJUANA CUTS SPASTICITY & PAIN THAT'S RESISTANT TO CONVENTIONAL TREATMENTS FOR MS PATIENTS"

Jody Corey-Bloom, M.D., PH.D
We saw a beneficial effect of
smoked cannabis on treatment
resistant spasticity and pain
associated with multiple sclerosis
among our participants
"
Spasticity scores on the modified Ashworth scale dropped by an average 2.74 points more with smoked cannabis than with a placebo, researchers at the University of California San Diego found, reports Crystal Phend at MedPage Today.

A difference or two or more points is considered clinically meaningful on the 30-point Ashworth scale which covers mobility of elbows, hips, and knees, report Jody Corey-Bloom, M.D., Ph.D., and colleagues at UCSD. The researchers reported their findings online in CMAJ.

Besides the positive effects on spasticity, pain scores decreased by about 50 percent as well, the researchers reported. “We saw a beneficial effect of smoked cannabis on treatment-resistant spasticity and pain associated with multiple sclerosis among our participants,” Corey-Bloom said.

The findings regarding smoked marijuana support anecdotal evidence from many MS patients who say smoking the herb relieves spasticity, the researchers noted. About 400,000 pepole in the United States have MS.


The body naturally produces cannabinoids, a group of chemicals also found in marijuana. Studies have suggested that the cannabinoid receptors on our cells help regulate muscle spasticity, reports Amy Norton of Reuters.
Read more »

Labels:


 

Popular Diets: What Docs Eat! What They Need to Know! 12 PHOTO SLIDESHOW

 

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments



This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.

DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Read more »

Labels: , , , , , , , , , ,


 

"PPMS: A New Hope?" by MS Patient & Ph.D: EMILY WILLINGHAM, PH.D.

Emily Willingham, Ph.D.

A blog post at a site run by UK MS researchers begins in a way that brings hope to the progressive MS crowd because, well, at least it actually mentions PPMS:

“… the progressive phase of MS is present from the beginning of the disease. How do we know this? Studies of MSers presenting with their first clinical attack already have significant brain atrophy on MRI and about 30-40% have subtle cognitive impairment. When you look even earlier in people diagnosed with
Read more »

 

Study: A urological challenge: Voiding dysfunction in multiple sclerosis.

This summary provides strategies to help reduce the impact of these symptoms.
Read more »

 

Study: Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis

Study results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression. Detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients
read more

 

Neuromyelitis Optics: Once thought of as a variant of multiple sclerosis, neuromyelitis optica is now clearly understood to be a different disease

 

Data shows treatment inequalities for EU's multiple sclerosis patients

Access to treatment and services varies remarkably for EU citizens diagnosed with multiple sclerosis, depending on which country they live in, according to a survey by the European Multiple Sclerosis Platform (EMSP).
Read more »

 

MS researchers find task meaningfulness influences learning and memory

 

Antibody may be detectable in blood years before multiple sclerosis symptoms appear

 

MSer Barbara Jordan began dealing with prejudices & she used them to fuel her success.

 

Clay Walker kicks off State Fair

 

Firefighters help one of their own to help pay the medical expenses for Jason Van Norman, a firefighter battling Multiple Sclerosis

 

Natural methods can help MS joint pain relief

 

Legalized Marijuana: Companies Moving Now To Cash In On Cannabis

Friday

 

Study: TEARS OF MSers CONTAIN HIGH LEVELS OF AN INFLAMATION-INHIBITING PROTIEN THAT MIGHT SERVE AS A DIAGNOSTIC BIOMARKER FOR MS

 
A safe and simple biomarker would be easier on both patients and doctors and possibly enable earlier diagnosis without
requiring expensive MRI imaging, and invasive lumbar punctures.

Cindy Salvisberg and colleagues at the Medical University Center of the University of Geneva, Switzerland, have uncovered a new MS biomarker that can be safely collected from patients’ tears. Their study appeared online ahead of print in Proteomics Clinical Applications (Salvisberg et al., 2014).
Read more »

 

Study: Remyelination: Are Exosomes Containing microRNA the Answer? Naturally produced exosomes with miRNA led to increased myelination in vitro and in vivo

 

Study: Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS

 

Merck went through a serious downsizing after its key multiple sclerosis drug candidate failed two years ago, slashing 1000's of jobs and closing its Swiss R&D operation and some plants

The drugmaker could use some new candidates since its setback from the failure of its once-high-profile MS therapy. Stimuvax, a cancer vaccine, also came up short in Phase III, although Merck will test it in a subgroup of patients. Garijo told Bloomberg his company is also developing a "super Erbitux" from a product it licensed from Symphogen. read more

 

‘Female Viagra’ finds difficult path at FDA

 

Study: Multiple Sclerosis Affects Women More than Men - link to an online video

 

Study: Comprehensive Eye Exams Can Help Identify Some Chronic Conditions, May Lead to Improved Health

 

Study: Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomized trial

 

Study: Naturally Occurring Packets Show Promise for Protecting Nerve Fibers in the Brain

 

A Dutch startup is collaborating with biotechnology companies to make it easier for patients with MS and unable to get into clinical trials to access potentially life saving drugs before they are cleared by regulators

 

Study: Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

 

This study provides Class III evidence that early treatment with IFNβ-1b is associated with prolonged survival in initially treatment-naive patients with relapsing-remitting multiple sclerosis

 

Insights into multiple sclerosis provided by non-coding RNAs: meeting summary from the symposium ‘Non-coding RNAs in autoimmune disorders of the central nervous system’ in Warsaw, Poland

Abstract:
Read more »

Thursday

 

Sensor detects MS at earliest stages, before onset of physical signs

 

Study: Head movement during fMRI may bias sampling toward subjects with lower cognitive ability

 

Study: Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

 

"COPAXONE IS HEADED OFF A CLIFF: It's painfully clear that generic competitors such as Mylan, Momenta, and Novartis' Sandoz unit will roll out generic Copaxone on time"

Oral MS drugs could exacerbate Copaxone's decline. Meanwhile, the three main oral MS drugs -- Novartis' Gilenya, Biogen's Tecfidera, and Sanofi's Aubagio -- could all bury Copaxone in its key U.S. market. Click to read how fast these treatments have been selling, despite their limited time on the market.

Labels: , , ,


 

Study: Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

 

STUDY: Neurofilament light antibodies in serum reflect response to Tysabri (natalizumab) treatment in multiple sclerosis

 

Study: Multiple Sclerosis Disease Progression and Paradichlorobenzene: A Tale of Mothballs and Toilet Cleaner

This case study illustrates that environmental causes for neurological deterioration should be investigated in MSers who display a rapidly progressive disease course and in whom potent pharmacotherapies fail. One possible cause is the ingestion of paradichlorobenzene-containing mothballs and toilet cleaners.click to read

 

Study: The anti-VLA-4 antibody Tysabri (natalizumab) induces erythroblastaemia in the majority of the treated MSers

 

An Innovative Self-Help Method For Multiple Sclerosis Patients Developed By Two Occupational Therapists

 

Foods That May Harm the Brain: This Medscape slideshow tells us what foods we should avoid to preserve our cognitive capacities and slow diseases of the brain.

 

Study: Women with multiple sclerosis MS & some depressive symptoms were found to have reduced size of the right hippocampus—a brain structure that helps regulate mood

 

Researchers have found a “potentially novel therapeutic target” to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis.

Wednesday

 

MORE BAD NEWS FOR COPAXONE: "TEVA IS OVEROPTIMISTIC ON NEW LARGE DOSAGE OF COPAXONE"

"Our survey results numerically suggest Teva Pharmaceutical Industries Ltd.'s targets are going to be hard to hit," says Royal Bank of Canada analyst Randall Stanicky about the company's three-times-a-week Copaxone. "Teva is targeting to have 40,000 patients on the three-times-a-week by year-end (reflects 47% of current patients) including 30,000 by end of May. The physicians we polled had direct dialogue with 14% of patients, on average, at this point regarding a potential switch and expect an average of 31% of their patients to move to the three-times-a-week," says Stanicky. The variance was very wide, from 0-70%. "Asked whether they would hold off moving patients in anticipation of a generic being made available in late May, 50% said they would," he adds.

Read more »

Labels:


 

Biogen may launch two new MS therapies this year: Plegridy & Daclizumab

The 1st of Biogen's 2 potential MS launches this year is Plegridy, a peg-interferon MS treatment filed for FDA approval last May. Plegridy put up solid data in late-stage studies, showing a 36% reduction in MS relapses versus placebo. Plegridy's favorable dosing regimen has Biogen thinking it could become a top seller. Industry analysts, who are predicting peak sales could eclipse $2 billion a year, seem to agree.
Finally, Biogen is co-developing daclizumab, another MS drug, with AbbVie. That once-a-month therapy reduced MS relapses by 54% in phase 2b trials. AbbVie hopes daclizumab can help support future sales growth and help offset competitive pressure on its blockbuster autoimmune drug, Humira. Morgan Stanley thinks daclizumab could rack up more than $700 million in sales by 2020. click to read


 

A New Treatment that Boosts Immunity to Epstein-Barr Virus may Benefit Patients with Multiple Sclerosis

 

Study: What do MSers & Their Caregivers Perceive as Unmet Needs?

 

B Cell Study May Lead to Treatment Options for Progressive MS

 

Mapi Pharma Granted US Patent for the Preparation of Fingolimod

 

Study: Does the patient know best? Quality of life assessment in MS trials

 

Study: Abnormalities of Motor Imagery & Relationship With Depression in RRMS

CONCLUSIONS: Our finding could be considered in the application of MI during the rehabilitation of persons with MS. click to read

 

Study: Impact of transcranial direct current stimulation on MSers fatigue

 

Study: Experience of an information aid for newly diagnosed MSers

 

When patient opinion & clinical science are opposed: the view from a MS specialist

 

Study: Is the incidence of optic neuritis rising?

 

Study: T cell repertoire following autologous stem cell transplantation for MS

 

Study: Daclizumab-induced adverse events in multiple organ systems in MS

 

Study: Obstructive sleep apnea very prevalent yet underrecognized cause of MS fatigue

Tuesday

 

STUDY: The changing fortunes of Tecfidera (dimethyl fumarate)

Key points of this study:
  • Dimethyl fumarate is thought to defend against oxidative stress-induced neuronal death and support myelin integrity.
  • Dimethyl fumarate has shown to reduce annual relapse rates in relapsing remitting MS compared to glatiramer acetate.
  • It may also have a positive effect on progression of disability and the number of gadolinium-enhancing lesions.
  • It is generally well tolerated, with flushing, gastro-intestinal upset, upper-respiratory tract infections and erythema/pruritis being the most common affects reported.
  • Oral administration, good tolerability and likely safety in liver and renal disease patients may make this an attractive addition to existing MS therapies.

Labels: , ,


 

58 year old woman with Multiple Sclerosis scammed out of $150,000

 

Dutch EX-neurologist Ernst Jansen jailed for wrongly diagnosing serious diseases such as Alzheimer's & multiple sclerosis

 

Sanofi has failed to win U.S. regulatory approval for its multiple sclerosis drug Lemtrada

 

Rhonda Voskuhl, M.D. from Synthetic Biologics to Present Trimesta™ Phase II Multiple Sclerosis Clinical Trial Results at AAN Annual Meeting 2014

 

Drug Abuse Among Doctors: Easy, Tempting, and Not Uncommon

 

Sleep Apnea is common with MSers and may contribute to their fatigue, a new study shows

Monday

 

Forbes analyzes how one doctor could defraud Medicare of $12 million: "The Money, the MD and a $12 Million Patient Safety Scandal"

 

3 years ago, Trevor Bayne shocked the world & made history by becoming the youngest driver ever to win the Daytona 500 and In November, the 22-year-old announced he has multiple sclerosis

 

Many MSers rely on drugmakers' assistance programs for help...BUT it's uncertain whether the help will be allowed for people who buy health insurance on the marketplaces established by the federal health law.

 

STUDY: Recombinant hepatitis B vaccine and the risk of multiple sclerosis

 

Eating a parasite might be the breakthrough we need to fight Crohn’s disease, multiple sclerosis

 

STUDY: MOST MSers ARE FEMALES SO THIS STUDY IS IMPORTANT: "Women who smoke just 100 cigarettes in their lifetime are '30% more likely to get breast cancer"


Many MSers who are social smokers believe they don't puff on enough cigarettes to be at risk of serious side effects. But new research shows that smoking just 100 cigarettes in a lifetime increases a woman's chance of developing breast cancer by 30 per cent.

The research also revealed that women between 20 and 44 years old who have smoked a pack of cigarettes a day for at least 10 years are 60 per cent more likely to develop the most common form of breast cancer. Read more



 

STUDY: First-line Tysabri (natalizumab) in multiple sclerosis: rationale, patient selection, benefits and risks

Abstract: Tysabri/Natalizumab is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis. Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal leukoencephalopathy (PML) has largely contributed to it being relegated to a second-line position. Health professionals only

Labels: , ,


 

STUDY: 37 per cent of people with mild MS are employed, however, many have to change or quit their jobs due to their fluctuating functional capability...75 per cent of MSers report that MS has impacted their employment and career opportunities

 

Advocates for MSers Push for Legislative Support for Medicaid Expansion

 

Study: Psychometric properties of quality of life and health-related quality of life assessments in MSers

 

Biogen Idec Inc: Tecfidera Continues Its Blistering Pace

The company's new oral alternative to its top-selling Avonex racked up $286 million in third quarter sales, far above the $200 million forecast by some industry analysts. Its rapid roll-out helped it capture $876 million in revenue in 2013, including $398 million in the fourth quarter. For comparison, in the most recent quarter reported, competitor drugs Gilenya earned $521 million and Aubagio by brought in about $60 million.  read more

Labels: , , ,


 

Thirty-year wait for Multiple Sclerosis drug Lemtrada drags on

 

Study: New blood cells fight brain inflammation

 

Study: Women with MS, Depression Show Alterations of Brain Structure

 

Study: THYROID DISEASE IS NOT JUST A PROBLEM WITH ALEMTUZUMAB

 "The study below highlights the problem in MSers starting interferon-beta of GA treatment and supports routine monitoring. As you should be aware thyroid disease is a major issue post alemtuzumab treatment with about 40% of woman and 20% of men developing autoimmune thyroid disease within 5 years of receiving the treatment. In this situation it is recommended that thyroid function in monitored every 3 months for up to, and possibly beyond, 4 years. This is not a trivial problem and MSers will need to be highly motivated to go the course."

Study: The increased prevalence Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetateof TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.
Read more »

 

Do Wheat and Dairy Make MS Flare-Ups Worse?

Sunday

 

Biogen Said to Name Papadopoulos as Chairman, Replacing Young

 

The fatigue felt by most Multiple Sclerosis patients could be caused by an undiagnosed sleep disorder rather than the MS itself

 

MIT Students Build Voice-recognition Device for Professor with Multiple Sclerosis

 

A Possible Target to Spur Remyelination of Nerves

 

Protein May Repair Damaged Brain Tissue In Multiple Sclerosis

 

Dementia: Is Gluten the Culprit?

 

Mediterranean Diet Improves Cognition

 

Genzyme’s MS drug Lemtrada approved in Mexico, but still no word on U.S. appeal

 

Study: Differential effects of Gilenya (fingolimod) on B-cell populations in multiple sclerosis

 

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

 

How are cognitive impairment, fatigue and signs of depression related to participation in daily life among persons with multiple sclerosis?

 

A multicenter research team led used a new, automated technique to identify shrinkage of a mood-regulating brain structure in a large sample of women with MS who also have a certain type of depression

 

Culinary Culprits: Foods That May Harm the Brain

Saturday

 
OUR SITE IS BEING REMODELED TODAY TO MAKE IT EASIER FOR YOU TO STAY ON  OUR WEBSITE EACH TIME YOU CLICK ON A LINK!!

BEFORE TODAY...EACH TIME YOU CLICKED ON A LINK TO GO TO AN OUTSIDE SOURCE...IT WAS DIFFICULT....BECAUSE YOU CLICKED ON THE LINK WE PROVIDED...THEN LEFT OUR SITE TO READ THE ENTIRE ARTICLE...BUT WHEN YOU WANTED TO COME BACK TO OUR SITE: YOU HAD TO PUT OUR URL BACK IN YOUR BROWSER!

NOW: YOU WILL AUTOMATICALLY STAY ON OUR SITE...WITHOUT DOING ANYTHING!!

OUR WEBMASTER DAVID HANNES IS WORKING ON CHANGING ALL 3,685 STORIES & STUDIES WE HAVE POSTED!

WE WILL BEGIN POSINT THE NEWS TONIGHT WHEN HE IS DONE!  HERE'S A FEW WORDS FROM OUR WEBMASTER:


Dave Hannes, Webmaster


"In order to provide a more satisfactory browsing experience I'm working on remodeling the site to  allow visitors to stay on the main page after they have finished reading and closed articles that they have opened in new windows! I hope you will enjoy reading the news better when you come back tomorrow"

Dave Hannes

Friday

 

Heather Tetzlaff Smith, Columnist, MSnewsChannel.com

Heather Tetzlaff Smith
I think my Column today is important for every MSer who has ever loved or dreams of love in a romantic context.

One of the hardest things for me to remember is that there are plenty of people who see and love me for me. They see beyond my MS and disability. I know it can be easy to give up on love.

I have found myself thinking “"i don't want to deal with my MS...so why would anyone else?"

That thinking is normal. But, that is just not true and only serves to create a block between myself and anyone that will truly love me beyond my physical capabilities.I choose to believe there is big romantic love in my future, indeed! It is Valentine’s Day and I have been reflecting on love and romance. I have learned and experienced so much over these 42 years.

I must admit that I have had quite an experience with some amazing romantic gestures. Here's 10 of my favorites:
Read more »

 
CONTROL OF SMALL PROTEIN MAY FIGHT MYELIN DAMAGE IN MULTIPLE SCLEROSIS
Endothelin-1 has long been recognized as a vasoconstrictor, which means it causes the muscle layer in the blood vessels to contract. This protein also has an ability to affect the central nervous system.
Read more »

 
Winter sports enthusiasts can enjoy the best Crystal Mountain has to offer, all while benefiting lifestyle empowerment programs for people living with multiple sclerosis 
Read more »

 
Last Week QIMR Berghofer Announced an Incredible Step Forward in a New Treatment for Multiple Sclerosis
LISTEN TO AUDIO HERE

     

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!


The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.

The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.

 In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.

MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov



Read more »

Labels: , , , , , , , , , , , ,


Thursday

 
Kari Rinker
MS GROUP ADVOCATES FOR EXPANSION OF MEDICAID
Advocates for people with multiple sclerosis spent much of Tuesday at the Statehouse, urging legislators to expand Medicaid.

Read more »

 
The Effect of an AFO-shaped Elastic Band on Drop-foot Gait in Patients with Central Neurological Lesions

Read more »

 
MSer Migrates to Pot Friendly States to Help to Improve His Quality of Life

Read more »

     

RISK OF MULTIPLE SCLEROSIS INCREASED WITH ADOLESCENT OBESITY AND HLA GENOTYPE

A number of factors are associated with an increased risk of developing adult-onset multiple sclerosis (MS), including modulated immune function, vitamin D insufficiency, the human leukocyte antigen (HLA) genotype, and interaction with the Epstein-Barr virus. Interestingly, some of these risk factors are also associated with being obese. Since obesity is also associated with low-grade chronic inflammation, it is projected that the risk of HLA-related activation of T-cells contributes to an autoimmune attack on the central nervous system, leading to MS.

Read more »

 

15 STUDIES IN THURSDAY'S NEWS

 PLUS: 1575 new Studies we posted from 11/1 to Wednesday 2/12 Start at the Bottom!




In patients with SSc, serum levels of ICAM-1 and P-selectin may serve as prognostic indicators of respiratory dysfunction and physical disability, respectively. Further longitudinal studies of larger populations are needed to confirm these findings.

Seizures can occur at any stage during the course of MS, but it is more common during the early stages.

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.

In the NARCOMS cohort, functional health literacy is high. However, lower levels of health literacy are associated with adverse health behaviors and greater health care utilization.
Read Study at Pubmed.gov

In the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , , , , ,


Wednesday

 
THE EFFECTS OF A LOW FAT DIET WITH ANTIOXIDANT SUPPLEMENTATION FOR PROGRESSIVE MS
Dietary supplements are involved in cell metabolism modulation and MS-related inflammatory processes. Consequently, low fat diets and antioxidant supplements may be used as complementary therapies for treatment of multiple sclerosis.
Read more »

 
EBV Adoptive Immunotherapy Shows Promise For Secondary Progressive Multiple Sclerosis
“The beneficial effect of boosting immunity to EBV by this treatment highlights the importance of impaired immunity to EBV in the development of MS. We believe the treatment corrects the impaired CD8 T cell immunity that allowed EBV infection to cause MS.”
Read more »

 
Factors Associated to the Work Situation of Patients with Multiple Sclerosis

Read more »

 
Components of Rehabilitation That are Helpful From the Perspective of Individuals with Multiple Sclerosis

Read more »

 
Advocates for the Approval of Lemtrada (Alemtezumab) Continue to Speak Up
Read more »

Labels:


     

15 STUDIES IN WEDNESDAY'S NEWS

 PLUS: 1560 new Studies we posted from 11/1 to Tuesday 2/11 Start at the Bottom!



Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed. 
Read Study at Pubmed.gov

The best current evidence for the efficacy of glucocorticoid treatment in MS, by far, comes from the optic neuritis treatment trial, which used high-dose intravenous methylprednisolone for the first 3 days followed by an 11-day course of low-dose oral prednisone. 
Read Study at Pubmed.gov

It is hoped that, through an understanding of the earliest aspects of the MS disease process, critical insights will be gained about the genesis of MS. 
Read Study at Pubmed.gov

Major technical improvements in MRI hardware and pulse sequence design allow more specific and potentially more sensitive treatment metrics required for targeting outcomes most relevant to neuronal degeneration, remyelination and repair. 
Read Study at Pubmed.gov

This chapter reviews the current evidence, taken from both clinical and paraclinical sources, as it relates to establishing this prognosis and provides insight to where, in the future, we need to look. 
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , , ,


Tuesday

 
MEDICAL MARIJUANA IS HITTING THE DEEP SOUTH AND GAINING TRACTION
"I'm an unlikely champion for this cause," said Georgia Rep. Allen Peake, a businessman from Macon who attended the evangelical Dallas Theological Seminary. "Once people realize it's not a 6-year-old smoking a joint, most folks realize this is the compassionate thing to do."
Read more »


Go to Newer News Go to Older News